EBV LMP-2A Antibodies

Santa Cruz Biotechnology features a diverse variety of EBV LMP-2A monoclonal antibodies for a variety of research applications. EBV LMP-2A Antibodies are validated for techniques such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). The Epstein-Barr virus (EBV) latent membrane protein 2A (LMP-2A) plays a crucial role in the virus's ability to evade the host immune response and establish latency. By modulating signaling pathways, LMP-2A contributes to the transformation of infected B cells and is implicated in the development of various EBV-associated malignancies. Understanding the function of EBV LMP-2A is essential for developing therapeutic strategies against EBV-related diseases. Research into EBV LMP-2A has revealed its significant impact on cell survival and proliferation mechanisms. Investigating LMP-2A interactions with cellular proteins provides valuable insights into viral persistence and oncogenesis. The molecular characterization of LMP-2A continues to unveil new potential therapeutic targets. Santa Cruz Biotechnology monoclonal antibodies for EBV LMP-2A support researchers worldwide in advancing our understanding of EBV-related diseases and potential treatments.